Metastatic and locally-advanced neuroendocrine neoplasms (aNEN) form clinically and
genetically heterogeneous malignancies, characterized by distinct prognoses based upon …

DNA sequencing has identified recurrent mutations that drive the aggressiveness of prostate
cancers. Surprisingly, the influence of genomic, epigenomic, and transcriptomic …

Chromothripsis and kataegis are frequently observed in cancer and may arise from telomere
crisis, a period of genome instability during tumorigenesis when depletion of the telomere …

Many primary tumours have low levels of molecular oxygen (hypoxia), and hypoxic tumours
respond poorly to therapy. Pan-cancer molecular hallmarks of tumour hypoxia remain poorly …

Oesophageal adenocarcinoma is a poor prognosis cancer and the molecular features
underpinning response to treatment remain unclear. We investigate whole genome …

Mutagenic processes leave distinct signatures in cancer genomes. The mutational
signatures attributed to APOBEC3 cytidine deaminases are pervasive in human cancers …

Gastrointestinal stromal tumor (GISTs) are clinically heterogenous exhibiting varying
degrees of disease aggressiveness in individual patients. We comprehensively describe the …

Background The utility of circulating tumour DNA (ctDNA) for longitudinal tumour monitoring
in pancreatic ductal adenocarcinoma (PDAC) has not been explored beyond mutations in …

Mutagenic processes leave distinct signatures in cancer genomes. The mutational
signatures attributed to APOBEC3 cytidine deaminases are pervasive in human cancers …

Rapid mutation fuels the evolution of many cancers and pathogens. Much of the ensuing
genetic variation is detrimental, but cells can survive by limiting the cost of accumulating …